Bisphosphonate-related jaw necrosis--severe complication in maxillofacial surgery.
Bisphosphonates are used as potent inhibitors in metastatic bone lesions. They can reduce skeletal burden and prevent bony metastases. They are integral in the treatment of some tumours like breast cancer, prostate cancer and multiple myeloma. As a side effect, these drugs also may cause severe jaw necrosis. Twenty-four patients with bisphosphonate-related jaw necrosis were analyzed in a clinical study. These necroses mostly appeared after administration of aminobisphosphonates. Recurrent avascular necroses were found after changing from Pramidronate to Zoledronate. All patients were treated by resection of necrotic bone. Repeated surgical interventions were required with about 25% of the patients. The management of patients with bisphosphonate-related jaw necrosis remains extremely difficult and includes surgical procedures as well as the eradicating of the necrotic bone including antibiotic therapy. The prevention of such complications consists in a minimization of dental surgical interventions and an avoidance of ulcers by dental prosthesis.
Eckert
A W
AW
Department of Oral and Maxillofacial Plastic Surgery, Martin-Luther-University Halle-Wittenberg, Ernst-Grube Street 40, 06097 Halle/Saale, Germany. aw.eckert.wissenschaft@web.de
Maurer
P
P
Meyer
L
L
Kriwalsky
M S
MS
Rohrberg
R
R
Schneider
D
D
Bilkenroth
U
U
Schubert
J
J
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007568:Jaw / Q000473:pathology*; D009336:Necrosis / Q000139:chemically induced / Q000517:prevention & control / Q000601:surgery; D012008:Recurrence
D004164:Diphosphonates